Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRSHIPEC)‎

Joint Authors

Gushchin, Vadim
Sardi, Armando
Munoz-Zuluaga, Carlos A.
Sittig, Michelle
King, Mary C.
Nieroda, Carol
Lopez-Ramirez, Felipe
Diaz-Montes, Teresa P.

Source

International Journal of Surgical Oncology

Issue

Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-14, 14 p.

Publisher

Hindawi Publishing Corporation

Publication Date

2020-12-17

Country of Publication

Egypt

No. of Pages

14

Main Subjects

Diseases
Medicine

Abstract EN

Background.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) after neoadjuvant chemotherapy (NACT) showed promise as initial treatment for stage IIIC (SIII) epithelial ovarian cancer (EOC); however, stage IV (SIV) outcomes are rarely reported.

We assessed our experience and outcomes treating newly diagnosed SIV EOC with NACT plus CRS/HIPEC compared to SIII patients.

Methods.

Advanced EOC from 2015–2018 managed with NACT (carboplatin/paclitaxel) due to unresectable disease or poor performance status followed by interval CRS/HIPEC were reviewed.

Perioperative factors were assessed.

Overall survival (OS) and progression-free survival (PFS) were analyzed by stage.

Results.

Twenty-seven FIGO stage IIIC (n = 12) and IV (n = 15) patients were reviewed.

Median NACT cycles were 3 and 4, respectively.

Post-NACT omental caking, ascites, and pleural effusions decreased/resolved in 91%, 91%, and 100% of SIII and 85%, 92%, and 71% of SIV.

SIII/SIV median PCI was 21 and 20 obtaining 92% and 100% complete cytoreduction (≤0.25 cm), respectively.

Median organ resections were 6 and 7, respectively.

Grade III/IV surgical complications were 0% SIII and 23% SIV, without hospital mortality.

Median time to adjuvant chemotherapy was 53 and 74 days, respectively (p=0.007).

SIII OS at 1 and 2 years was 100% and 83% and 87% and 76% in SIV (p=0.269).

SIII 1-year PFS was 54%; median PFS: 12 months.

SIV 1- and 2- year PFS was 47% and 23%; median PFS: 12 months (p=0.944).

Conclusion.

Outcomes in select initially diagnosed and unresectable SIV EOC are similar to SIII after NACT plus CRS/HIPEC.

SIV EOC may benefit from CRS/HIPEC, and further studies should explore this treatment approach.

American Psychological Association (APA)

Munoz-Zuluaga, Carlos A.& Sardi, Armando& Sittig, Michelle& Gushchin, Vadim& King, Mary C.& Nieroda, Carol…[et al.]. 2020. Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRSHIPEC). International Journal of Surgical Oncology،Vol. 2020, no. 2020, pp.1-14.
https://search.emarefa.net/detail/BIM-1174153

Modern Language Association (MLA)

Munoz-Zuluaga, Carlos A.…[et al.]. Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRSHIPEC). International Journal of Surgical Oncology No. 2020 (2020), pp.1-14.
https://search.emarefa.net/detail/BIM-1174153

American Medical Association (AMA)

Munoz-Zuluaga, Carlos A.& Sardi, Armando& Sittig, Michelle& Gushchin, Vadim& King, Mary C.& Nieroda, Carol…[et al.]. Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRSHIPEC). International Journal of Surgical Oncology. 2020. Vol. 2020, no. 2020, pp.1-14.
https://search.emarefa.net/detail/BIM-1174153

Data Type

Journal Articles

Language

English

Notes

Includes bibliographical references

Record ID

BIM-1174153